Drug Profile
INOC 001
Alternative Names: BIO 103; INOC001Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator Avantogen Oncology
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Jun 2006 Innovate Oncology is now a wholly owned subsidiary of Avantogen
- 30 May 2006 Innovate Oncology has been acquired by Avantogen
- 13 May 2005 Phase-I/II clinical trials in Cancer in USA (unspecified route)